An anti-tumor drug promotes weight loss in mice at low doses by activating a natural hunger-suppressing pathway, according to a new study. The results provide a promising new avenue for development of anti-obesity treatments.

Ultrasound scans — best known for monitoring pregnancies or imaging organs — can also be used to stimulate cells and direct cell function. A team of researchers has developed an easier, more effective way to harness the technology for biomedical applications.

Researchers have uncovered how a process involved in the regeneration of tissue damaged by radiation can aid the spread of cancer.

Scientists say the unexpected discovery about small-cell lung cancer could lead to new treatment approaches for that cancer and other forms of cancer as well.

Gut bacteria brew all sorts of chemicals, but we don’t know what most of them do. A new study suggests that one such compound, previously linked to cancer, may serve as a bizarre weapon in microbial skirmishes.

A new study shows how certain RNA molecules control the repair of damaged DNA in cancer cells, a discovery that could eventually give rise to better cancer treatments.

Some genetic mutations linked to leukemia are less than useful guides to making treatment decisions for patients. A new study suggests a group of clinical signs that can be paired with genetic testing to better inform the timing of more aggressive treatment.

Over 90 percent of patients with transfusion-dependent thalassemia, an inherited blood disorder, no longer needed monthly blood transfusions years after receiving gene therapy, according to an international Phase 3 clinical trial that for the first time included children younger than 12 years of age. Twenty-two patients were evaluated (ranging in age 4-34 years), including pediatric patients.

Researchers developed a radio-labeled molecule that allows real-time PET imaging of inflammation and activation of innate immune activity. This would allow physicians to pinpoint areas of inflammation in a variety of clinical settings before symptoms appear.

A research group has discovered the logic that controls gene regulation in human cells. In the future, this new knowledge can be applied to, for example, investigating cancers and other genetic diseases.

Little has been known to date about how the immune system’s natural killer (NK) cells detect which cells have been infected with SARS-CoV-2. Scientists now show that NK cells respond to a certain peptide on the surface of infected cells. The study is an important piece of the puzzle in our understanding of how the immune system reacts to COVID-19.

In the long-term battle between a herpesvirus and its human host, a virologist and her team of students have identified some human RNA able to resist the viral takeover — and the mechanism by which that occurs.

T-cell responses directed against the receptor-binding domain of the SARS-CoV-2 spike protein were associated with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers, according to a new study.

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer.

Acute myeloid leukemia, which affects blood and bone marrow cells, is a particularly dangerous form of cancer. More than half of patients under the age of 60 die. This proportion rises to 85% for patients over 60. A team has now identified a previously unknown mechanism that could lead to the development of new therapies. The selective activation of AMPK, a key enzyme in the energy balance of tumor cells, would indeed lead to their death by triggering the cells stress response. Moreover, the scientists have successfully exploited this energy gap in an animal model of the disease: a combination of two drugs — one of which is already on the market — has indeed shown promise. However, their effectiveness has yet to be confirmed on leukaemia stem cells, which have the ability to escape many treatments to restart tumor growth.

Annual MRI screenings starting at ages 30 to 35 may reduce breast-cancer mortality by more than 50% among women who carry certain genetic changes in three genes, according to a comparative modeling analysis. The predictions involve pathogenic variants in ATM, CHEK2 and PALB2 genes — which collectively are as prevalent as the much-reported BRCA1/2 gene mutations.

A team of researchers has discovered blood biomarkers that can potentially predict patient response in the treatment of melanoma.

A new study adds to a growing body of evidence that organoids — lab-grown collections of cells that mimic a patient’s tumor — are a promising avenue for drug discovery to improve outcomes in patients with cancer, particularly rare cancers for which clinical data on drug effectiveness is often lacking.

A future vaccine providing protection against a wide range of coronaviruses that jump from their original animal hosts to humans — including SARS-CoV-2, the cause of COVID-19 — may be possible, say researchers.

Scientists have developed mathematical models that act as patient ’surrogates‘ for evaluating potential prostate cancer treatments.

Researchers found that some cancer cells weave a deactivating signal into a protective coat of armor, immobilizing and excluding T cells that would otherwise kill them. This immune deactivation pathway offers a promising new therapeutic approach for pancreatic, breast, and colorectal cancers.

Researchers surveyed and compared early- and late-stage breast and colorectal cancer diagnoses in patients in pre-pandemic 2019 and in 2020, the first full year of the COVID-19 pandemic, discovering fewer of the former and more of the latter as patients delayed care.

A new study shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.

A study is validating the use of genomic sequencing to predict the likelihood that patients with gastric cancer will derive benefit from chemotherapy or from immunotherapy.

A new study found in a living embryo that the back ends of moving cell groups push the group forward, with implications for how organs form and cancer spreads.